SAN DIEGO - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a $6.5 billion biotech company with exceptional financial health according to InvestingPro metrics, announced today that argenx has received ...

Company News Published 06/20/2025, 01:22 PM 0 Argenx receives EU approval for VYVGART subcutaneous injection HALO 0.30% ...

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme ...

A subcutaneous injection is an injection into the fatty tissue. There are many types, and people use them to treat diabetes and other conditions. Learn more about subcutaneous injections ...

Session ID: 2025-07-03:3cf1bb11724c03f9a2bec1d7 Player Element ID: V68f2216e_1b7e_46c7_a5c4_9742710e3757_6372862962112 ...

"We are delighted that the subcutaneous injection of VYVGART® co-formulated with our ENHANZE drug delivery technology, has been recommended for approval in the European Union.

By Halozyme Therapeutics, Inc. Apr 28, 2025 Apr 28, 2025Updated Apr 28, 2025 ...

Additionally, subcutaneous injections are much quicker than IV infusions. This may save some time in the clinic, although the healthcare team may also want to monitor people for some time after ...

He also went on to add his thoughts on how this may impact treatment adherence and quality of life for patients receiving immunotherapy. Notably, this interview came following the Dec. 27, 2024, Food ...

The recommended dosing for subcutaneous nivolumab varies by indication: 600 mg of nivolumab with 10,000 units of hyaluronidase every 2 weeks, 900 mg of nivolumab with 15,000 units of hyaluronidase ...

Eisai, Lilly innovate Alzheimers treatment with subcutaneous injection forms Eisai and Lilly push boundaries in the race for improved Alzheimers therapies through innovative delivery methods.